LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

Search

Aurinia Pharmaceuticals Inc

Open

SectorHealthcare

15.92 0.38

Overview

Share price change

24h

Current

Min

15.85

Max

16.12

Key metrics

By Trading Economics

Income

-176M

34M

Sales

591K

78M

P/E

Sector Avg

7.088

49.888

EPS

0.25

Profit margin

44.212

Employees

128

EBITDA

2.7M

50M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

-1.07% downside

Dividends

By Dow Jones

Next Earnings

30 Jul 2026

Market Stats

By TradingEconomics

Market Cap

-80M

2B

Previous open

15.54

Previous close

15.92

News Sentiment

By Acuity

50%

50%

139 / 344 Healthcare

Aurinia Pharmaceuticals Inc Chart

Past performance is not a reliable indicator of future results.

Related News

14 Mar 2026, 00:29 UTC

Acquisitions, Mergers, Takeovers

13D Filings -- Barrons.com

3 Nov 2025, 09:49 UTC

Hot Stocks

Stocks to Watch Monday: Berkshire Hathaway, Onsemi, Palantir -- WSJ

Peer Comparison

Price change

Aurinia Pharmaceuticals Inc Forecast

Price Target

By TipRanks

-1.07% downside

12 Months Forecast

Average 15.67 USD  -1.07%

High 17 USD

Low 15 USD

Based on 3 Wall Street analysts offering 12 month price targets forAurinia Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

3 ratings

1

Buy

2

Hold

0

Sell

Sentiment

By Acuity

139 / 344 Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.
help-icon Live chat